Patent foramen ovale closure with the Gore septal occluder: initial UK experience.
OBJECTIVES: To report procedural outcome and short-term follow-up data for the Gore septal occluder (GSO), a new device for closure of patent foramen ovale (PFO). BACKGROUND: Transcatheter closure of PFO is an established treatment modality but no current device provides a perfect solution. The GSO...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2014
|
| _version_ | 1797052078191804416 |
|---|---|
| author | Thomson, J Hildick-Smith, D Clift, P Morgan, G Daniels, M Henderson, R Spence, MS Mahadevan, V Crossland, D Ormerod, O |
| author_facet | Thomson, J Hildick-Smith, D Clift, P Morgan, G Daniels, M Henderson, R Spence, MS Mahadevan, V Crossland, D Ormerod, O |
| author_sort | Thomson, J |
| collection | OXFORD |
| description | OBJECTIVES: To report procedural outcome and short-term follow-up data for the Gore septal occluder (GSO), a new device for closure of patent foramen ovale (PFO). BACKGROUND: Transcatheter closure of PFO is an established treatment modality but no current device provides a perfect solution. The GSO has a number of design features, which make it potentially attractive for closure of defects in the atrial septum. METHODS: Data from 9 centers in the United Kingdom implanting the GSO device, submitted to an electronic registry for evaluation. RESULTS: Two hundred twenty-nine patients undergoing PFO closure from June 2011 to October 2012 were included. Indications for closure were secondary prevention of paradoxical cerebral emboli (83.4%), migraine (2.1%), platypnoea orthodeoxia (3.9%), and other (10.5%). Median PFO size was 8 mm and 34 and 39%, respectively, had long tunnel anatomy or atrial septal aneurysms. A GSO was successfully implanted in all cases. A single device was used in 98% but in 4 patients the initial device was removed and a second device required. Procedural complications occurred in 3% and later complications (e.g., atrial fibrillation, atrial ectopics, and device thrombus) in 5.7% of cases. All patients have undergone clinical and echocardiographic follow-up and all devices remain in position. Early bubble studies (median 0 months) with Valsalva maneuver in 67.2% were negative in 89%. CONCLUSIONS: The GSO is an effective occlusion device for closure of PFO of all types. Longer-term follow-up particularly to document later closure rates are required. |
| first_indexed | 2024-03-06T18:27:44Z |
| format | Journal article |
| id | oxford-uuid:0890b073-9bc7-49f2-95f8-5c57aa36dda3 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T18:27:44Z |
| publishDate | 2014 |
| record_format | dspace |
| spelling | oxford-uuid:0890b073-9bc7-49f2-95f8-5c57aa36dda32022-03-26T09:13:33ZPatent foramen ovale closure with the Gore septal occluder: initial UK experience.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:0890b073-9bc7-49f2-95f8-5c57aa36dda3EnglishSymplectic Elements at Oxford2014Thomson, JHildick-Smith, DClift, PMorgan, GDaniels, MHenderson, RSpence, MSMahadevan, VCrossland, DOrmerod, OOBJECTIVES: To report procedural outcome and short-term follow-up data for the Gore septal occluder (GSO), a new device for closure of patent foramen ovale (PFO). BACKGROUND: Transcatheter closure of PFO is an established treatment modality but no current device provides a perfect solution. The GSO has a number of design features, which make it potentially attractive for closure of defects in the atrial septum. METHODS: Data from 9 centers in the United Kingdom implanting the GSO device, submitted to an electronic registry for evaluation. RESULTS: Two hundred twenty-nine patients undergoing PFO closure from June 2011 to October 2012 were included. Indications for closure were secondary prevention of paradoxical cerebral emboli (83.4%), migraine (2.1%), platypnoea orthodeoxia (3.9%), and other (10.5%). Median PFO size was 8 mm and 34 and 39%, respectively, had long tunnel anatomy or atrial septal aneurysms. A GSO was successfully implanted in all cases. A single device was used in 98% but in 4 patients the initial device was removed and a second device required. Procedural complications occurred in 3% and later complications (e.g., atrial fibrillation, atrial ectopics, and device thrombus) in 5.7% of cases. All patients have undergone clinical and echocardiographic follow-up and all devices remain in position. Early bubble studies (median 0 months) with Valsalva maneuver in 67.2% were negative in 89%. CONCLUSIONS: The GSO is an effective occlusion device for closure of PFO of all types. Longer-term follow-up particularly to document later closure rates are required. |
| spellingShingle | Thomson, J Hildick-Smith, D Clift, P Morgan, G Daniels, M Henderson, R Spence, MS Mahadevan, V Crossland, D Ormerod, O Patent foramen ovale closure with the Gore septal occluder: initial UK experience. |
| title | Patent foramen ovale closure with the Gore septal occluder: initial UK experience. |
| title_full | Patent foramen ovale closure with the Gore septal occluder: initial UK experience. |
| title_fullStr | Patent foramen ovale closure with the Gore septal occluder: initial UK experience. |
| title_full_unstemmed | Patent foramen ovale closure with the Gore septal occluder: initial UK experience. |
| title_short | Patent foramen ovale closure with the Gore septal occluder: initial UK experience. |
| title_sort | patent foramen ovale closure with the gore septal occluder initial uk experience |
| work_keys_str_mv | AT thomsonj patentforamenovaleclosurewiththegoreseptaloccluderinitialukexperience AT hildicksmithd patentforamenovaleclosurewiththegoreseptaloccluderinitialukexperience AT cliftp patentforamenovaleclosurewiththegoreseptaloccluderinitialukexperience AT morgang patentforamenovaleclosurewiththegoreseptaloccluderinitialukexperience AT danielsm patentforamenovaleclosurewiththegoreseptaloccluderinitialukexperience AT hendersonr patentforamenovaleclosurewiththegoreseptaloccluderinitialukexperience AT spencems patentforamenovaleclosurewiththegoreseptaloccluderinitialukexperience AT mahadevanv patentforamenovaleclosurewiththegoreseptaloccluderinitialukexperience AT crosslandd patentforamenovaleclosurewiththegoreseptaloccluderinitialukexperience AT ormerodo patentforamenovaleclosurewiththegoreseptaloccluderinitialukexperience |